Helicobacter pylori (H. pylori), which infects about 50% of the global population, has been recognized as a main risk factor of multiple gastric pathologies, especially non-cardiac gastric cancer. Strongly evidence supports that H. pylori eradication is an effective approach to reduce the incidence of those pathologies.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
120
amoxicillin 1000 mg bid. for 14 days
clarithromycin 500 mg bid. for 14 days.
tinidazole 500 mg bid. for 14 days.
Eradication rate of AST guided triple therapy
Time frame: 3 months
the rate of improving dyspepsia symptoms after H. pylori eradication
Time frame: 3 months
the rate of adverse events happening
Time frame: 3 months
the rate of good compliance (take pills more than 90%)
Time frame: 3 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
levofloxacin 500 mg qd. for 14 days.
furazolidone 100 mg bid. for 14 days.
tetracycline 750 mg bid. for 14 days.
Ilaprazole 5 mg bid. for 14 days.